Heart MRI monitoring for immunotherapy-related heart issues
Part of Heart & circulation, Injuries & trauma clinical trials.
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have been diagnosed with a gynecologic cancer (like ovarian, uterine, or cervical cancer).
- You are about to start immunotherapy (a drug that helps your immune system fight cancer).
- You have not had immunotherapy before.
- You are able to have an MRI scan (no metal implants, pacemakers, or severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic factors that may affect the risk of heart inflammation (myocarditis) caused by immune checkpoint inhibitors (ICIs), a type of cancer immunotherapy. It aims to find out if your genes make you more likely to develop this side effect.
This study looks at heart health in people who have finished immunotherapy for melanoma. It uses MRI scans to check for any heart problems that may have developed after treatment.
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
This study looks at whether certain immunotherapy drugs (nivolumab, pembrolizumab, or ipilimumab) affect the heart in people with skin cancer. You will have special heart imaging to check for any early signs of heart problems.
This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.
This study follows people who had a heart-related side effect from immunotherapy and are now ready for rehab. It aims to better understand recovery and guide treatment.
Hear when a new Immune Checkpoint Inhibitors, Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.